Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 19/20 | 1.00 |
| ▸ | MTOR | P42345 | 19/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 14/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.80 |
| ▸ | ATR | Q13535 | 5/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17246416 | 1.00 | ATM (1.00) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17272545 | 0.98 | ATM (1.00) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17246378 | 0.98 | ATM (1.00) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17272488 | 0.91 | ATM (1.00) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17272490 | 0.91 | ATM (1.00) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17243235 | 0.90 | ATM (1.00) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17243234 | 0.90 | ATM (1.00) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17242478 | 0.89 | MTOR (1.00) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17246335 | 0.89 | ATM (1.00) | ATMMTORPIK3CAKCNH2ATR | |
| SCHEMBL17272533 | 0.89 | ATM (1.00) | ATMMTORPIK3CAKCNH2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3140303-B1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | claimed |
| US-9822111-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | claimed |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2016-12-22 | — | — | US | claimed |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2015-11-26 | — | — | US | claimed |
| US-20230256110-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-08-17 | — | — | US | disclosed |
| CN-116194109-A | Combination of antibody-drug conjugate and ATM inhibitor | 阿斯利康(英国)有限公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4171651-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | AstraZeneca UK Limited (GB) | 2023-05-03 | — | — | EP | disclosed |
| WO-2021260580-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-20190185468-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2019-06-20 | — | — | US | disclosed |
| US-10189834-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-01-29 | — | — | US | disclosed |
| US-20180134699-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA UK LIMITED (GB) | 2018-05-17 | — | — | US | disclosed |
| EP-3140303-B1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| EP-3140303-B1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| US-9822111-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2017-11-21 | — | — | US | disclosed |
| EP-3140303-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2016-12-22 | — | — | US | disclosed |
| US-9428503-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating Cancer | ASTRAZENECA AB (SE) | 2016-08-30 | — | — | US | disclosed |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2015-11-26 | — | — | US | disclosed |
| WO-2015170081-A1 | IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2015-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134699-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | ATM 1/4885MTOR 393/4885PIK3CA 229/4885 |
| US-20230256110-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR | ATM, CHEK2, ERBB2 | ATM 1/4885MTOR 506/4885PIK3CA 1071/4885 |
| US-20190185468-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | ATM 1/4885MTOR 393/4885PIK3CA 229/4885 |
| US-20160368920-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | ATM 1/4885MTOR 393/4885PIK3CA 229/4885 |
| US-20150336952-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, CHEK2, CHEK1 | ATM 1/4885MTOR 393/4885PIK3CA 229/4885 |
| US-10189834-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, CHEK2, CHEK1 | ATM 1/4885MTOR 393/4885PIK3CA 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.